Kroll D J, Sullivan D M, Gutierrez-Hartmann A, Hoeffler J P
Division of Medical Oncology, University of Colorado Health Sciences Center, Denver 80262.
Mol Endocrinol. 1993 Mar;7(3):305-18. doi: 10.1210/mend.7.3.8387155.
DNA topoisomerase II (topo II) is an essential nuclear enzyme which catalyzes the interconversions of various forms of DNA. As predicted from the human topo II cDNA, the enzyme contains a potential leucine zipper protein dimerization motif. We therefore tested whether topo II could enter protein-protein interactions with other better characterized leucine zipper-containing proteins and determined if these interactions could modify topo II enzymatic activity in vitro. By far Western analyses, a large C-terminal fragment of human topo II was shown to interact with the DNA binding and dimerization regions of either cAMP response element binding protein (CREB) or the activating transcription factor-2. The C-terminal topo II fragment also interacted with full-length c-Jun, but not with full-length c-Fos. Using CREB as a prototype, the effect of this interaction on various topo II catalytic activities was assessed in vitro. CREB, at a 1- to 10-fold molar excess relative to topo II, inhibited site-specific DNA cleavage activity on a 242-base pair fragment of the human alpha-glycoprotein hormone subunit gene promoter. Very high CREB concentrations (400-fold excess) apparently inhibited topo II DNA relaxation activity, but this result was likely a direct effect of CREB on the topology of the DNA substrate. More interestingly, a 10-fold molar excess of CREB stimulated topo II decatenation activity, the essential function of this enzyme in cell division. This stimulatory effect could also be elicited by c-Jun, which interacts with topo II, but not by c-Fos, which does not bind topo II in our in vitro assay. Since similar amounts of CREB reduced the abundance of topo II DNA cleavage products from the human alpha-CG promoter yet also stimulated decatenation activity, it can be concluded that either: 1) CREB stimulated the religation rate of topo II; or 2) CREB directed topo II to a new cleavage site present on the decatenation substrate but not present on the limited alpha-CG promoter. The structural requirements for topo II protein-protein interactions were also investigated. Site-directed mutations which destroyed the putative topo II leucine zipper did not disrupt topo II protein-protein interactions. Since the putative leucine zipper in topo II does not appear to mediate protein-protein interactions, we propose that an alternate as yet uncharacterized structure is involved in the association of topo II with itself and other regulatory proteins.
DNA拓扑异构酶II(拓扑异构酶II)是一种必需的核酶,可催化DNA各种形式的相互转化。正如从人类拓扑异构酶II cDNA所预测的那样,该酶含有一个潜在的亮氨酸拉链蛋白二聚化基序。因此,我们测试了拓扑异构酶II是否能与其他特征更明确的含亮氨酸拉链的蛋白发生蛋白质-蛋白质相互作用,并确定这些相互作用是否能在体外改变拓扑异构酶II的酶活性。通过远缘Western分析,人类拓扑异构酶II的一个大的C末端片段被证明能与环磷酸腺苷反应元件结合蛋白(CREB)或激活转录因子-2的DNA结合和二聚化区域相互作用。拓扑异构酶II的C末端片段也能与全长的c-Jun相互作用,但不能与全长的c-Fos相互作用。以CREB为原型,在体外评估了这种相互作用对各种拓扑异构酶II催化活性的影响。相对于拓扑异构酶II,CREB以1至10倍的摩尔过量,抑制了人类α-糖蛋白激素亚基基因启动子242碱基对片段上的位点特异性DNA切割活性。非常高浓度的CREB(400倍过量)明显抑制了拓扑异构酶II的DNA松弛活性,但这个结果可能是CREB对DNA底物拓扑结构的直接影响。更有趣的是,10倍摩尔过量的CREB刺激了拓扑异构酶II的解连环活性,这是该酶在细胞分裂中的基本功能。c-Jun也能引发这种刺激作用,它与拓扑异构酶II相互作用,但c-Fos不能,在我们的体外实验中c-Fos不与拓扑异构酶II结合。由于相似量的CREB减少了来自人类α-CG启动子的拓扑异构酶II DNA切割产物的丰度,但同时也刺激了解连环活性,因此可以得出结论:要么1)CREB刺激了拓扑异构酶II的再连接速率;要么2)CREB将拓扑异构酶II导向解连环底物上存在但有限的α-CG启动子上不存在的一个新的切割位点。还研究了拓扑异构酶II蛋白质-蛋白质相互作用的结构要求。破坏假定的拓扑异构酶II亮氨酸拉链的定点突变并没有破坏拓扑异构酶II的蛋白质-蛋白质相互作用。由于拓扑异构酶II中假定的亮氨酸拉链似乎并不介导蛋白质-蛋白质相互作用,我们提出一种尚未明确的替代结构参与了拓扑异构酶II与自身及其他调节蛋白的结合。